Literature DB >> 20144743

Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice.

Sivasami Pulavendran1, Jayarajan Vignesh, Chellan Rose.   

Abstract

Bone marrow stem cells nullify acquired and non-acquired diseases of liver through multiple strategies including antiinflammation. However, little is known about the in vivo mechanism of immunomodulation by stem cells in mediating liver cirrhosis. Mesenchymal stem cells (MSC) or hematopoietic stem cells (HSC) isolated from bone marrow of male mice were transplanted into female mice with acute liver inflammation. Serum levels of liver proteins and aminotransferase as well as hepatic antioxidant enzymes were estimated. Immunostaining for the expression of tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), alpha smooth muscle actin (alpha-SMA) and type I collagen proteins was carried out and the expression of these mRNAs was also studied. After post-transplantation, the levels of serum albumin and aminotransferases became normal and the levels of antioxidants were significantly high in the MSC treated mice compared to HSC and control mice. Necrotic cells and invasion of neutrophils were not observed in histological sections of liver of MSC treated mice. Immunostaining showed that IL-6 and TNF-alpha were not expressed in the MSC treated mice when compared to the control and HSC treated mice. alpha-SMA representing activated myofibroblasts and type I collagen were not expressed in MSC treated group. These inflammatory and fibrogenic results were further confirmed by reverse transcription-polymerase chain reaction (RT-PCR). The acute inflammation ended with the formation of fibrosis in the HSC and control groups by the uncontrolled immunoreactions. Protection mechanism of MSC therapy against injury and fibrosis in the liver occurs by the suppression of inflammation. Our findings suggest that bone marrow MSC are capable of alleviating the immunoreactions leading to the fibrosis in the liver. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144743     DOI: 10.1016/j.intimp.2010.01.014

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

1.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

2.  Therapeutic potential effect of bone marrow-derived mesenchymal stem cells on chronic liver disease in murine Schistosomiasis Mansoni.

Authors:  Mohamed H Hegab; Somia H Abd-Allah; Maha S Badawey; Ayman A Saleh; Ashraf S Metwally; Ghada M Fathy; Soad M Nada; Sara A Abdel-Rahman; Amira A Saleh; Amal Fawzy; Mohammed Abu El-Magd
Journal:  J Parasit Dis       Date:  2018-04-23

3.  Optical imaging of subacute airway remodeling and adipose stem cell engraftment after airway injury.

Authors:  Yeh-Chan Ahn; Sung Won Kim; Sang Seok Hwang; Yu-Gyeong Chae; Andrew Sungwan Lee; Maan Hong Jung; Bong Kwon Chun; Sang Joon Lee; Eun-Kee Park; Chulho Oak
Journal:  Biomed Opt Express       Date:  2013-12-20       Impact factor: 3.732

4.  Bone marrow stem-cell therapy for genetic and chronic liver diseases.

Authors:  Veena Kochat; Prakash Baligar; Rakhi Maiwall; Asok Mukhopadhyay
Journal:  Hepatol Int       Date:  2014-01-03       Impact factor: 6.047

5.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

6.  Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats.

Authors:  Yu Wang; Fan Lian; Jiaping Li; Wenzhe Fan; Hanshi Xu; Xiuyan Yang; Liuqin Liang; Wei Chen; Jianyong Yang
Journal:  J Transl Med       Date:  2012-06-26       Impact factor: 5.531

7.  Hepatocyte growth factor incorporated chitosan nanoparticles augment the differentiation of stem cell into hepatocytes for the recovery of liver cirrhosis in mice.

Authors:  Sivasami Pulavendran; Chellan Rose; Asit Baran Mandal
Journal:  J Nanobiotechnology       Date:  2011-04-28       Impact factor: 10.435

8.  Mesenchymal stem cells: from experiment to clinic.

Authors:  William R Otto; Nicholas A Wright
Journal:  Fibrogenesis Tissue Repair       Date:  2011-09-08

Review 9.  Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.

Authors:  Chenxia Hu; Lingfei Zhao; Lanjuan Li
Journal:  J Mol Med (Berl)       Date:  2021-01-02       Impact factor: 4.599

10.  In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury.

Authors:  Qiang Li; Xinmin Zhou; Yongquan Shi; Jinge Li; Linhua Zheng; Lina Cui; Jun Zhang; Lu Wang; Zheyi Han; Ying Han; Daiming Fan
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.